Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-229666 in allergic conjunctivitis
NCT02082262Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alcaftadine in allergic conjunctivitis (AC), sponsored by Allergan. Primary endpoint: Change From Baseline In Ocular Itching Frequency at 70 days. Started Mar 2014; status: completed.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02082262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082262.